INTRODUCTION
Historically, transcatheter aortic valve replacement (TAVR) has been
used to treat patients with aortic stenosis, deemed high risk for
surgical aortic valve replacement1. Recently,
indications for TAVR have been expanded to intermediate and low-risk
patients, and the use of TAVR in patients with aortic insufficiency is
now being explored2. In this report, we will present
and discuss the methodology employed in two cases of severe, symptomatic
aortic insufficiency that underwent TAVR as treatment of pathology after
being deemed prohibitive risk by an experienced Heart Valve team. The
use of a Balloon-expandable Edwards SAPIEN valve to stabilize the
initial deployment of a self-expandable Medtronic Evolut value is
described.